Blocking of Fatty Acid Amide Hydrolase Activity with PF-04457845 in Human Brain: A Positron Emission Tomography Study with the Novel Radioligand [11C]CURB

FAAH genetic variation enhances fronto-amygdala function in mouse and human

(2015) Iva Dincheva et al.   Nature Communications

Whole-Body Radiation Dosimetry of 11C-Carbonyl-URB694: A PET Tracer for Fatty Acid Amide Hydrolase

(2014) I. Boileau et al.   JOURNAL OF NUCLEAR MEDICINE

Radiosynthesis and ex vivo evaluation of [11C-carbonyl]carbamate- and urea-based monoacylglycerol lipase inhibitors

(2014) Justin W. Hicks et al.   NUCLEAR MEDICINE AND BIOLOGY

Latest advances in the discovery of fatty acid amide hydrolase inhibitors

(2013) Tiziana Bisogno et al.   Expert Opinion on Drug Discovery

Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study

(2013) A Neumeister et al.   MOLECULAR PSYCHIATRY

More surprises lying ahead. The endocannabinoids keep us guessing

(2013) Daniele Piomelli   NEUROPHARMACOLOGY

Inhibition of FAAH and activation of PPAR: New approaches to the treatment of cognitive dysfunction and drug addiction

(2013) Leigh V. Panlilio et al.   PHARMACOLOGY & THERAPEUTICS

Amygdala FAAH and anandamide: mediating protection and recovery from stress

(2013) Ozge Gunduz-Cinar et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Covalent inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by the carbamates JZL184 and URB597

(2012) J. Allen Crow et al.   BIOCHEMICAL PHARMACOLOGY

The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB1- and FAAH-independent mechanisms

(2012) Barbara Bosier et al.   BRITISH JOURNAL OF PHARMACOLOGY

Mapping Human Brain Fatty Acid Amide Hydrolase Activity with PET

(2012) Pablo M Rusjan et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Radiosynthesis and Evaluation of [11C-Carbonyl]-Labeled Carbamates as Fatty Acid Amide Hydrolase Radiotracers for Positron Emission Tomography

(2012) Alan A. Wilson et al.   JOURNAL OF MEDICINAL CHEMISTRY

Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography

(2012) J Hirvonen et al.   MOLECULAR PSYCHIATRY

Endocannabinoid system: Potential novel targets for treatment of schizophrenia

(2012) Atsushi Saito et al.   NEUROBIOLOGY OF DISEASE

Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects

(2011) Gai Ling Li et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain

(2011) K. Ahn et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

[11C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography

(2010) Alan A. Wilson et al.   NUCLEAR MEDICINE AND BIOLOGY

Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor

(2010) Douglas S. Johnson et al.   ACS Medicinal Chemistry Letters

Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain

(2009) Kay Ahn et al.   CHEMISTRY & BIOLOGY

A Second Generation of Carbamate-Based Fatty Acid Amide Hydrolase Inhibitors with Improved Activity in vivo

(2009) Jason R. Clapper et al.   ChemMedChem

Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders

(2009) Kay Ahn et al.   Expert Opinion on Drug Discovery

Direct fixation of [11C]-CO2by amines: formation of [11C-carbonyl]-methylcarbamates

(2009) Alan A. Wilson et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Discovery and Development of Fatty Acid Amide Hydrolase (FAAH) Inhibitors

(2008) Mark Seierstad et al.   JOURNAL OF MEDICINAL CHEMISTRY